Azithromycin for COVID-19 Treatment in Outpatients Nationwide

• Status: Terminated
• Trial end date: 2021-03-30
• Target enrollment: 0
• Participant gender: All

Summary

This individually randomized telemedicine-based trial aims to evaluate the efficacy of a single dose of azithromycin for prevention of progression of COVID-19 in patients with a recent positive SARS-CoV-2 test who are not currently hospitalized.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Thomas M. Lietman; University of California, San Francisco
• Collaborators: Bill and Melinda Gates Foundation; Pfizer; Stanford University
• Treatments: Azithromycin

Criteria

Inclusion Criteria:

• Evidence of a positive SARS-CoV-2 test and test results received within the previous seven days

• Not currently hospitalized

• Willing and able to receive study drug by mail

• Willing and able to do the study questionnaires at baseline, day 3, 7, 14, 21 days via email or over the phone

• No known allergy or other contraindication to macrolides

• Age 18 years or older at the time of enrollment

• No known history of prolongation of the QT interval (eg. History of torsades de pointes, congenital long QT syndrome, bradyarrhthmia)

• No recent use of hydroxychloroquine within the past 7 days for participants >55 years of age

• Not currently taking nelfinavir or warfarin (Coumadin)

• Provision of informed consent

• Not currently pregnant